Quest Diagnostics Incorporate (DGX) has been experiencing a good performance as evidenced by increased acquisitions, investing interests, positive earnings and strong guidance.
The New York Stock Exchange (NYSE:DGX) has seen massive investments and partnership announcements such as collaboration with Broad Clinical Labs, Choose Healthy Life and BD, pursuing innovation and combating health disparities. Following their
quarterly cash dividends announcement, and a series of acquisitions, such as LifeLabs and lab assets from OhioHealth and Allina Health, the company consistently raised its full-year guidance for 2024. Furthermore, DGX's EPS surpassed market expectations and they declared multiple dividends quarterly. The strategic acquisitions have led to faster adoption of AI and digital pathology in cancer diagnosis. DGX has been acknowledged as a Best Place to Work for Disability Inclusion, which is a nod to its corporate social responsibility. The company also introduced specimen self-collection across its nationwide network of service centers further expanding its service reach. Overall, various shareholders have increased their positions in the company which indicates
strong financial prospects and attractiveness to investors.
Quest Diagnostics DGX News Analytics from Tue, 02 Apr 2024 07:00:00 GMT to Sat, 30 Nov 2024 14:29:48 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor 6
